Industries > Pharma > The Molecular Diagnostics (MDx) Market Forecast 2017-2027

The Molecular Diagnostics (MDx) Market Forecast 2017-2027

Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing

PUBLISHED: 08 August 2017
PAGES: 206
PRODUCT CODE: PHA0222

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The molecular diagnostics (MDx) market was worth $6.13bn in 2016 and is estimated to grow at a CAGR of 12.5% from 2017-2021. The fastest growing segment of the molecular diagnostics market over the forecast period 2017-2027 will be the oncology testing segment. The segment was worth $1.08bn in 2016 and represented 17.6% of the molecular diagnostics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 135 charts – all unavailable elsewhere.

The 206-page report provides clear detailed insight into the molecular diagnostics (MDx) market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

World IVD market forecasts from 2017-2027

Molecular diagnostics (MDx) market forecasts from 2017-2027

The Molecular Diagnostics (MDx) Market Forecast 2017-2027

Revenue and growth forecasts to 2027 for the leading submarkets:
• Infectious Disease Testing
• Oncology Testing
• Blood Screening
• Genetic Testing
• Tissue Typing

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– Europe:
• Germany
• UK
• Spain
• Italy
• France
• Rest of Europe
– Japan
– China
– Brazil
– Russia
– India
– South Korea
– Mexico
– RoW

• This report discusses the leading companies in the molecular diagnostics (MDx) market:
• Roche Diagnostics
• Qiagen
• Hologic
• Becton, Dickinson & Company
• bioMérieux
• Agilent Technologies

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Analysis of assays and instruments currently on the market as well as pipeline products
• Acquisitions and strategic partnerships

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the molecular diagnostics (MDx) market

Visiongain’s study is intended for anyone requiring commercial analyses for the molecular diagnostics (MDx). You find data, trends and predictions.

Buy our report today The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for The Molecular Diagnostics (MDx) Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for The Molecular Diagnostics (MDx) Market Forecast 2017-2027


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category